Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497268 | 0.88 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL82791 | 0.88 | GRIN1 (0.48) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL82792 | 0.88 | GRIN1 (0.48) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL5506542 | 0.88 | GRIN1 (0.48) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL5538246 | 0.88 | GRIN1 (0.48) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL81946 | 0.86 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL3805223 | 0.86 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL83032 | 0.83 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2TSHRLMNAMAPT | |
| SCHEMBL497266 | 0.82 | MOGAT2 (0.39) | ALDH1A1SMN1; SMN2TSHRLMNACYP2D6 | |
| SCHEMBL27684474 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRLMNACYP2D6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129377-B2 | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-1805164-B9 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-07 | — | — | EP | disclosed |
| EP-1805164-B1 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2266969-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2261224-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | ALDH1A1 3276/4885SMN1; SMN2 25/4885TSHR 4516/4885 |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, PSEN1 | ALDH1A1 1955/4885SMN1; SMN2 674/4885TSHR 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.